September 21-22, 2026 | Washington, D.C.

Gaylord National harbor convention center and hotel

The bioeconomy is increasingly constrained by execution at scale.

The United States leads in industrial biotechnology discovery and early innovation but has struggled to consistently translate that advantage into deployed, commercial capacity. Projects stall between pilot and production, constrained by infrastructure, financing, supply chain fragmentation, and inconsistent demand signals.

This Summit brings together the leaders positioned to change that outcome: those building facilities, financing infrastructure, shaping procurement, and working to turn fragmented capability into functioning industry.

The question is no longer what is possible in the lab, rather, “what can be built, financed, and operated at commercial scale before global competitors lock in industrial-scale capacity?”